Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metabolic Diseases: early-phase trial registry
6 of 13 indexed Metabolic Diseases trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 6 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Metabolic Diseases: 13 US clinical trials tracked, 6 recruiting.
Metabolic Diseases is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 2 of these trials.
Enrollment posture brief
Registry condition metabolic-diseases
OPEN 6 | RECR 46% | LATE 2 | EARLY 4 | RANK #1315 | SPON 2
Volume-matched condition peers
Nearest open-share peer: B-cell Lymphoma (46% recruiting · 39 trials)
Metabolic Diseases lists 6 open slots (46% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metabolic Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metabolic Diseases recruits in line with its size-band peers.
6 of 13 indexed trials (46.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metabolic Diseases research.
Massachusetts General Hospital accounts for 2 of 13 trials (15.4%). 12 distinct sponsors appear on at least one study for this condition label.
-
Most Metabolic Diseases trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 13 trials that report a genuine target (sentinel values excluded). 9 of those (69.2%) plan for fewer than 100 participants.
-
Metabolic Diseases research is mostly interventional.
10 interventional and 3 observational studies make up this index (76.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
Genetic and Metabolic Disease in Children
University of Texas Southwestern Medical Center
NCT02650622
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
C5 Biomedical
NCT06674980
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
Massachusetts General Hospital
NCT06003153
The Effect of Processing on Food Reward
Virginia Polytechnic Institute and State University
NCT06017986
Effects of HIIT vs. TRE on Type 2 Diabetes Risk
Syracuse University
NCT07215533
Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular Zinc
University of California, Davis
NCT05236374
Intestinal Metabolic Reprogramming as a Key Mechanism of Gastric Bypass in Humans
University of Pittsburgh
NCT02710370
Adipose Tissue and Polycystic Ovary Syndrome (PCOS)(EIFFEL)
AdventHealth Translational Research Institute
NCT01745471
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
Kastle Therapeutics
NCT00694109
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
Pfizer
NCT01301456
Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00119379
Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test
Massachusetts General Hospital
NCT04958109
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
Catabasis Pharmaceuticals
NCT01968720
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metabolic Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metabolic Diseases trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metabolic Diseases page
13 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Metabolic Diseases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Massachusetts General Hospital sponsors the most Metabolic Diseases trials on record, review their full trial history before evaluating a specific study. See Massachusetts General Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metabolic Diseases condition card totals 13 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.